Lung Cancer Medicare Access to Precise Testing Act

This bill amends the Medicare program to require coverage of lung cancer biomarker testing. It adds lung cancer biomarker testing as a covered service under Medicare Part B and sets payment at 100 percent of reasonable charges for such testing.

Sec. 2, Requiring coverage of lung cancer biomarker testing under Medicare: This section adds lung cancer biomarker testing to the list of covered medical services under Medicare. It defines lung cancer biomarker testing as a test furnished on or after January 1, 2027, to an individual diagnosed with lung cancer, for identifying one or more specific biomarkers (such as genes, proteins, or other molecules) based on analysis of the individual's tissue, blood, or bodily fluids. The section also specifies that Medicare will pay 100 percent of the reasonable charges for this testing.